Protective effect of tetrandrine on doxorubicin-induced cardiotoxicity in rats

Tumori

Volumn 96, Issue 3, 2010, Pages 460-464

  Xu, Meng ^a   Sheng, Lianghe ^a   Zhu, Xinhai ^a   Zeng, Shibin ^a   Chi, Dexiang ^a   Zhang, Guo Jun ^a  

^a JINAN UNIVERSITY   (China)

Author keywords

Cardiotoxicity; Doxorubicin; Oxidative phosphorylation; Tetrandrine

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; DOXORUBICIN; TETRANDRINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CONTROLLED STUDY; ELECTROCARDIOGRAM; HEART FUNCTION; HEART LEFT VENTRICLE DP-DT; HEART MITOCHONDRION; HEART MUSCLE CONTRACTILITY; HEART PROTECTION; HEMODYNAMIC PARAMETERS; MITOCHONDRIAL RESPIRATION; NONHUMAN; PROTEIN PHOSPHORYLATION; QT PROLONGATION; RAT; TRANSMISSION ELECTRON MICROSCOPY;

EID: 77954961184     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089161009600314     Document Type: Article

References (20)

1. Barry E, Alavarez JA, Scully RE, Miller TL, Lipsultz SE: Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opin Pharmacother, 8: 1039-1058, 2007.
2. Gianni L, Herman EH, Lipshultz SE, Minotti G, Sarvazyan N, Sawyer DB: Anthracycline cardiotoxicity: from bench to bedside. J Clin Oncol, 26: 3777-3784, 2008.
3. Adams MJ, Lipshultz SE: Pathophysiology of anthracycline and radiation-associated cardiomyopathies: implications for screening and prevention. Pediatr Blood Cancer, 44: 600-606, 2005.
4. Berthiaume JM, Wallace KB: Adriamycin-induced oxidative mitochondrial cardiotoxicity. Cell Biol Toxicol, 23: 15-25, 2007.
5. Zuppinger C, Timolati F, Suter TM: Pathophysiology and diagnosis of cancer drug induced cardiomyopathy. Cardiovasc Toxicol, 7: 61-66, 2007.
6. Tomas S, Matin S, Olga P, Michaela A, Radomir H, Vladimir G: Anthracyline-induced cardiotoxicity: Overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep, 61: 154-171, 2009.
7. Chen YJ: Potential role of tetrandrine in cancer therapy. Acta Pharmacol Sin, 23: 1102-1106, 2002.
8. Xu M, Zhou P: An experimental study of Tetrandrine for reversal of drug resistance and counteraction of apoptosis in lung cancer chemotherapy. New J Trad Chin Med, 38: 90-91, 2006.
9. Singal PK, Iliskovic N: Doxorubicin-induced cardiomyopathy. New Engl J Med, 339: 900-905, 1998.
10. Arola OJ, Saraste A, Pulkki K: Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. Cancer Res, 60: 1789-1792, 2000.
11. Menna P, Salvatorelli E, Minotti G: Cardiotoxicity of antitumor drugs. Chem Res Toxicol, 21: 978-989, 2008.
12. Wu JM, Chen Y, Chen JC, Lin TY, Tseng SH: Tetrandrine induces apoptosis and growth suppression of colon cancer cells in mice. Cancer Lett, 287: 187-195 2010.
13. Rao MR: Effects of tetrandrine on cardiac and vascular remodeling. Acta Pharmacol Sin, 23: 1075-1085, 2002.
14. Yao WX, Jiang MX: Effects of tetrandrine on cardiovascular electrophysiologic properties. Acta Pharmacol Sin, 23: 1069-1074, 2002.
15. Zhou S, Starkov A, Froberg MK, Lerino RL, Wallace KB: Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin. Cancer Res, 61: 771-777, 2001.
16. Cao YH, Kennedy R, Klimberg VS: Glutamine protects against doxorubicin-induced cardiotoxicity. J Surg Res, 85: 178-182, 1999.
17. Alberts DS, Muggia FM, Carmichael J,Winter EP, Jahanzeb M, Venook AP, Skubitz KM, Rivera E, Sparano JA, DiBella NJ, Stewart SJ, Kavanagh JJ, Gabizon AA: Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials. Semin Oncol, 31: 53-90, 2004.
18. Sadzuka Y, Sugiyama T, Shimoi K, Kinae N, Hirota S: Protective effect of flavonoids on doxorubicin-induced cardiotoxicity. Toxicol Lett, 92: 1-7, 1997.
19. Santos DL, Moreno AJM, Leino RL, Froberg MK, Wallace KB: Carvedilol protects against doxorubicin-induced mitochondrial cardiomyopathy. Toxicol Appl Pharm, 185: 218-227, 2002.
20. Della Torre P, Bernardi C, Podesta A, Moneta D, Riflettuto M, Mazue G: Cardioprotection by dexrazoxane in rats treated with doxorubicin and paclitaxel. Cancer Chemother Pharmacol, 44: 138-142, 1999.